Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study

Research output: Contribution to journalJournal articlepeer-review

  1. A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia

    Research output: Contribution to journalJournal articlepeer-review

  2. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articlepeer-review

  3. Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

OBJECTIVES: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and the durability of vaccine-induced antibodies.

METHODS: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase 4 study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90, and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 after first vaccination. Nondurable vaccine response was defined as day-90 responders who no longer had significant responses by day 180.

RESULTS: Of 6544 participants completing two vaccine doses (median age 64 years; interquartile range: 54-75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by an mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hyporesponsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG and 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type, and number of comorbidities were associated with all four outcomes. Additionally, age ≥75 years was associated with hyporesponsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds ratio: 1.59; 95% confidence interval: 1.25-2.01) but not for Spike IgG.

DISCUSSION: Comorbidity, male sex, and vaccine type were risk factors for hyporesponsiveness and nondurable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-second-vaccination levels for most individuals after 6 months.

Original languageEnglish
JournalClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Issue number8
Pages (from-to)1126-1133
Number of pages8
Publication statusPublished - Aug 2022

Bibliographical note

Copyright © 2022. Published by Elsevier Ltd.

    Research areas

  • Aged, Angiotensin-Converting Enzyme 2, Antibodies, Blocking, Antibodies, Viral/blood, COVID-19 Vaccines/immunology, COVID-19/epidemiology, Comorbidity, Denmark/epidemiology, Female, Humans, Immunoglobulin G, Male, Middle Aged, SARS-CoV-2, Spike Glycoprotein, Coronavirus/immunology, Vaccination, mRNA Vaccines

ID: 75599083